EUVIMEDObjevte EUVIMED
Open access · CC BY 3.0

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Filippo Francini, Alessandra Pascucci, Edoardo Francini, Gianluca Bargagli, Raffaele Conca, Antonella Licchetta, Giandomenico Roviello, Ignazio Martellucci, Giorgio Chiriacò, Salvatora Tindara Miano, Giuseppe Marzocca, Antonio Manganelli and 3 more

Prostate Cancer · 2011

DOI: 10.1155/2011/258689 ↗

At a glance

Journal article in Prostate Cancer, 2011. Written by Filippo Francini and 14 co-authors. Institution: Department of Odontostomatology and Maxillo-Facial Surgery, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, Italy. Cited 13 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 3.0).

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Background

The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D.

Methods

Treatment consisted of D 30 mg/m 2 i.v. for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5 mg/kg i.v. every 2 weeks.

Results

Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02). After a median followup of 11.3 months, only five patients had died. The regimen was generally well tolerated.

Conclusion

Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy.

Authors and institutions

  • Department of Odontostomatology and Maxillo-Facial Surgery, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, Italy.

Cite

APA

Francini, F., Pascucci, A., Francini, E., Bargagli, G., Conca, R., Licchetta, A., Roviello, G., Martellucci, I., Chiriacò, G., Miano, S. T., Marzocca, G., Manganelli, A., Ponchietti, R., Savelli, V., & Petrioli, R. (2011). Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel. Prostate Cancer. https://doi.org/10.1155/2011/258689

Vancouver

Francini F, Pascucci A, Francini E, Bargagli G, Conca R, Licchetta A, et al. Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel. Prostate Cancer. 2011. doi:10.1155/2011/258689

BibTeX
@article{Francini2011,
  author = {Francini, Filippo and Pascucci, Alessandra and Francini, Edoardo and Bargagli, Gianluca and Conca, Raffaele and Licchetta, Antonella and Roviello, Giandomenico and Martellucci, Ignazio and Chiriacò, Giorgio and Miano, Salvatora Tindara and Marzocca, Giuseppe and Manganelli, Antonio and Ponchietti, Roberto and Savelli, Vinno and Petrioli, Roberto},
  title = {Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel},
  journal = {Prostate Cancer},
  year = {2011},
  doi = {10.1155/2011/258689}
}
Start for free →